Announcement

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (07-21-2016)
Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 (07-19-2016)
Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration... Continue Reading

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (07-18-2016)
The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric... Continue Reading

Anne Arundel Medical Center

Please click here to visit the DeCesaris Cancer Institute website

The DeCesaris Cancer Institute and AAMC Oncology and Hematology are now QOPI (Quality Oncology Practice Initiative) Certified. This demonstrates a commitment to excellence and ongoing quality improvement.
The goals of the QOPI Certification Program are:

1. Promote the highest quality cancer care as defined by the clinician experts.
2. Provide a trusted solution to satisfy external demand for quality activities.
3. Reduce redundant programs or requirements for oncology practices, including health plan programs.